496 research outputs found

    Utilization of Liquid Chromatography/Mass Spectrometry to Detect Drug Residues in Milk: Applications for Research and Commercial Dairying

    Get PDF
    Prevention of drug residues in milk is a daily endeavor on dairy farms. There is increasing scrutiny from the public and government when it comes to drug residues in milk. Drug residues can result from simple human errors, disease processes not allowing for normal clearance of a drug, or malicious activity. The testing methodologies used to detect drug residues have become more sensitive with many tests available that can detect drug levels below ten parts per billion (ppb)

    Topical Flunixin Meglumine Effects on Pain Associated Biomarkers after Dehorning

    Get PDF
    Twenty-four calves were dehorned and treated with either topical flunixin meglumine formulated for systemic absorption or a placebo. Biomarkers associated with pain were evaluated for up to 72 hour after the dehorning procedure. Plasma cortisol concentrations, 90 minutes post-dehorning, and mechanical nociception threshold at the control site were the only tested biomarkers where a significant difference was demonstrated. No other differences of biomarkers between the two dehorned groups were observed for any time points. Although this product is easy to dose and dispense, its effects on pain biomarkers appears to be negligible

    A study to examine the relationship between uterine pathology and depletion of oxytetracycline in plasma and milk after intrauterine infusion

    Get PDF
    Citation: Gorden, P. J., Ydstie, J., Kleinhenz, M. D., Wulf, L. W., Gehring, R., Wang, C., & Coetzee, J. F. (2016). A study to examine the relationship between uterine pathology and depletion of oxytetracycline in plasma and milk after intrauterine infusion. Journal of Animal Science, 94, 30-30. doi:10.2527/msasas2016-065Metritis is a frequent problem in postpartum dairy cows. Intrauterine therapy with oxytetracycline (OTC) is often used to improve therapeutic outcomes, although efficacy data supporting this therapy are ambiguous. Several manuscripts describe the depletion of OTC from milk following intrauterine therapy. However, none of these studies have correlated uterine severity scores with milk OTC concentrations using highly sensitive detection systems. Our objective was to do this to test the hypothesis that cows with more severe uterine severity would have higher OTC residues in milk following intrauterine therapy. Thirty-two cows received a single treatment of 4 g of OTC via intrauterine infusion. Blood and milk samples were collected before intrauterine therapy and throughout the trial period of 96 h after infusion. Uterine severity scores were assigned at initiation of therapy and every 24 h throughout the remainder of the trial. Plasma and milk samples were analyzed for OTC concentrations using liquid chromatography coupled with mass spectrometry. Following treatment, OTC rapidly diffused from the uterus to plasma and from plasma to milk. Maximum concentration in plasma and milk occurred within 24 h following intrauterine infusion and 18 of the cows still had detectable levels of OTC in milk 4 d after intrauterine infusion. Greater uterine severity score at the initiation of treatment showed a significant positively correlation with higher milk OTC concentration at the second milking following treatment (R2 = 0.46, P = 0.01) but there was no correlation between initial uterine severity score and OTC concentration at the conclusion of the study (R2 = ?0.06, P = 0.75). In the United States, intrauterine administration of OTC is considered to be an extra-label therapy. The use of uterine severity score can be used to predict OTC concentration in the first day following therapy but should not be used as a predictor of OTC concentrations 96 h after treatment. Dairy producers should consult with their veterinarian to develop strategies that will prevent the presence of violative residues of OTC in bulk tank milk following intrauterine therapy

    Understanding signaling cascades in melanoma

    Get PDF
    Understanding regulatory pathways involved in melanoma development and progression has advanced significantly in recent years. It is now appreciated that melanoma is the result of complex changes in multiple signaling pathways that affect growth control, metabolism, motility and the ability to escape cell death programs. Here we review the major signaling pathways currently known to be deregulated in melanoma with an implication to its development and progression. Among these pathways are Ras, B-Raf, MEK, PTEN, phosphatidylinositol-3 kinase (PI3Ks) and Akt which are constitutively activated in a significant number of melanoma tumors, in most cases due to genomic change. Other pathways discussed in this review include the [Janus kinase/signal transducer and activator of transcription (JAK/STAT), transforming growth factor-beta pathways which are also activated in melanoma, although the underlying mechanism is not yet clear. As a paradigm for remodeled signaling pathways, melanoma also offers a unique opportunity for targeted drug development.Fil: Lopez Bergami, Pablo Roberto. Sanford-burnham Medical Research Institute; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Fitchmann, B. Sanford-burnham Medical Research Institute; Estados UnidosFil: Ronai, Ze´ev. Sanford-burnham Medical Research Institute; Estados Unido

    Mutations in 3 genes (MKS3, CC2D2A and RPGRIP1L) cause COACH syndrome (Joubert syndrome with congenital hepatic fibrosis)

    Get PDF
    OBJECTIVE: To identify genetic causes of COACH syndrome BACKGROUND: COACH syndrome is a rare autosomal recessive disorder characterised by Cerebellar vermis hypoplasia, Oligophrenia (developmental delay/mental retardation), Ataxia, Coloboma, and Hepatic fibrosis. The vermis hypoplasia falls in a spectrum of mid-hindbrain malformation called the molar tooth sign (MTS), making COACH a Joubert syndrome related disorder (JSRD). METHODS: In a cohort of 251 families with JSRD, 26 subjects in 23 families met criteria for COACH syndrome, defined as JSRD plus clinically apparent liver disease. Diagnostic criteria for JSRD were clinical findings (intellectual impairment, hypotonia, ataxia) plus supportive brain imaging findings (MTS or cerebellar vermis hypoplasia). MKS3/TMEM67 was sequenced in all subjects for whom DNA was available. In COACH subjects without MKS3 mutations, CC2D2A, RPGRIP1L and CEP290 were also sequenced. RESUlTS: 19/23 families (83%) with COACH syndrome carried MKS3 mutations, compared to 2/209 (1%) with JSRD but no liver disease. Two other families with COACH carried CC2D2A mutations, one family carried RPGRIP1L mutations, and one lacked mutations in MKS3, CC2D2A, RPGRIP1L and CEP290. Liver biopsies from three subjects, each with mutations in one of the three genes, revealed changes within the congenital hepatic fibrosis/ductal plate malformation spectrum. In JSRD with and without liver disease, MKS3 mutations account for 21/232 families (9%). CONCLUSIONS: Mutations in MKS3 are responsible for the majority of COACH syndrome, with minor contributions from CC2D2A and RPGRIP1L; therefore, MKS3 should be the first gene tested in patients with JSRD plus liver disease and/or coloboma, followed by CC2D2A and RPGRIP1L

    The use of focus group discussion methodology: Insights from two decades of application in conservation

    Get PDF
    This is the final version of the article. Available from Wiley via the DOI in this recordFocus group discussion is frequently used as a qualitative approach to gain an in-depth understanding of social issues. The method aims to obtain data from a purposely selected group of individuals rather than from a statistically representative sample of a broader population. Even though the application of this method in conservation research has been extensive, there are no critical assessment of the application of the technique. In addition, there are no readily available guidelines for conservation researchers. Here, we reviewed the applications of focus group discussion within biodiversity and conservation research between 1996 and April 2017. We begin with a brief explanation of the technique for first-time users. We then discuss in detail the empirical applications of this technique in conservation based on a structured literature review (using Scopus). The screening process resulted in 170 articles, the majority of which (67%, n = 114,) were published between 2011 and 2017. Rarely was the method used as a stand-alone technique. The number of participants per focus group (where reported) ranged from 3 to 21 participants with a median of 10 participants. There were seven (median) focus group meetings per study. Focus group discussion sessions lasted for 90 (median) minutes. Four main themes emerged from the review: understanding of people's perspectives regarding conservation (32%), followed by the assessment of conservation and livelihoods practices (21%), examination of challenges and impacts of resource management interventions (19%) and documenting the value of indigenous knowledge systems (16%). Most of the studies were in Africa (n = 76), followed by Asia (n = 44), and Europe (n = 30). We noted serious gaps in the reporting of the methodological details in the reviewed papers. More than half of the studies (n = 101) did not report the sample size and group size (n = 93), whereas 54 studies did not mention the number of focus group discussion sessions while reporting results. Rarely have the studies provided any information on the rationale for choosing the technique. We have provided guidelines to improve the standard of reporting and future application of the technique for conservation.N.T.O. was funded by Cambridge Overseas Trusts, The Wildlife Conservation Society, Wildlife Conservation Network and WildiZe Foundation. NM was funded by the NERC grant (NE/R006946/1), Fondation Wiener Anspach and the Scriven post doctoral fellowships. K.W. was sup-ported by the Australian Research Council Centre of Excellence for Environmental Decisions (CE11001000104) and Future Fellowship (FT100100413) programs and funded by the Australian Government

    Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1

    Get PDF
    We studied the relationship between IL28B gene-related SNP rs12979860 and early viral kinetics (day 0–28) during peginterferon and ribavirin treatment, in 173 African Americans (AA) and 188 Caucasian Americans (CA) with HCV genotype 1

    A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates

    Get PDF
    Sorafenib monotherapy in patients with metastatic melanoma was explored in this multi-institutional phase II study. In correlative studies the impact of sorafenib on cyclin D1 and Ki67 was assessed. mutational status and clinical activity. No significant changes in expression of cyclin D1 or Ki67 with sorafenib treatment were demonstrable in the 15 patients with pre-and post-treatment tumor samples. mutational status of the tumor was not associated with clinical activity and no significant effect of sorafenib on cyclin D1 or Ki67 was seen, suggesting that sorafenib is not an effective BRAF inhibitor or that additional signaling pathways are equally important in the patients who benefit from sorafenib
    • …
    corecore